Systemic Arthritis and Prolonged Corticosteroid Use Associated with Growth Impairment in Juvenile Idiopathic Arthritis

Systemic Arthritis and Prolonged Corticosteroid Use Associated with Growth Impairment in Juvenile Idiopathic Arthritis

A recent study showed that children with juvenile idiopathic arthritis (JIA) now have similar growth and weight gain as children in the general population. Nonetheless, about 1 in 10 JIA children with systemic arthritis, uncontrolled disease, or prolonged use of corticosteroids had an increased risk of growth impairment.

The findings were reported in a study titled, “Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort,” published in the journal Pediatric Rheumatology

JIA is one of the most common rheumatic disorders affecting children and is known to influence a child’s growth and weight gain. It is believed that modern treatments have improved growth in children with JIA.

To confirm this hypothesis, researchers analyzed data from a program called “Research in Arthritis in Canadian Children emphasizing Outcomes,” or ReACCh-Out, with JIA patients diagnosed for the first time between 2005 and 2010 at 16 Canadian pediatric rheumatology centers. In total, 1,147 children were included in the study and followed for a median of 35.5 months.

Weight and height measurements were taken every six months for two years, and then every year for up to five years.

Age- and sex-standardized scores were calculated for weight, height, and body mass index (BMI) using Canadian Pediatric Endocrinology Group standards. Data on disease activity and medication used were collected by a pediatric rheumatologist at each visit and in-between study visits.

Overall, researchers found that mean scores for height, weight, and BMI remained relatively the same for the entire group. In total, 33 children (2.9%) developed a short stature, while 27 (2.4%) had a tall stature.

Of the children with systemic arthritis, which affects the entire body, 9.3% had an estimated three-year cumulative incidence of short stature, and 34.4% were obese.

The majority of children studied (81.7%) received no corticosteroids as treatment. However, 1 mg/Kg/day prednisone-equivalent (prednisone is a corticosteroid) treatment for six months led to a reduction of 0.64 in height scores, and an increase of 0.74 in BMI scores.

The incidence of short stature in children with prolonged steroid use was 6.6% in three years, compared with 2.6% in those not using steroids. The incidence of obesity also was higher, at 25% in three years for prolonged steroid users compared with 8.5% in non-users.

“Most children in this modern JIA cohort grew and gained weight as children in the general population. About 1 in 10 children who had systemic arthritis, uncontrolled disease and/or prolonged corticosteroid use, had increased risk of growth impairment,” the team stated. “These children may benefit from earlier aggressive therapy to help prevent growth impairment, or early consultation with a pediatric endocrinologist to mitigate growth impairment by other means.”

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?